ABT-450

From Wikipedia, the free encyclopedia
Jump to: navigation, search

ABT-450 is an acylsulfonamide[1] inhibitor of the NS3-4A serine protease[2] manufactured by Abbott Laboratories[3] that shows promising results as a treatment of hepatitis C. When given in combination with ritonavir and ribavirin for 12 weeks, the rate of sustained virologic response at 24 weeks after treatment has been estimated to be 95% for those with hepatitis C virus genotype 1.[4] Resistance to treatment with ABT-450 is uncommon, because it targets the binding site, but has been seen to arise due to mutations at positions 155 and 168 in NS3.[5]p. 248

References[edit]

  1. ^ Seng-Lai Tan and Yupeng He, ed. (2011). Hepatitis C: antiviral drug discovery and development. Norfolk: Caister academic press. p. 210. ISBN 9781904455783. Retrieved 28 April 2014. 
  2. ^ Donald Jensen, Nancy Reau, ed. (2013). Hepatitis C. New York: Oxford University Press. p. 144. ISBN 9780199844296. Retrieved 28 April 2014. 
  3. ^ "Abbott Announces Phase 3 Hepatitis C Program Details". Abbott company website. Abbott Laboratories. Retrieved 28 April 2014. 
  4. ^ Kowdley, Kris V.; Lawitz, Eric; Poordad, Fred; Cohen, Daniel E.; Nelson, David R.; Zeuzem, Stefan; Everson, Gregory T.; Kwo, Paul; Foster, Graham R.; Sulkowski, Mark S.; Xie, Wangang; Pilot-Matias, Tami; Liossis, George; Larsen, Lois; Khatri, Amit; Podsadecki, Thomas; Bernstein, Barry (2014). "Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1". New England Journal of Medicine 370 (3): 222–232. doi:10.1056/NEJMoa1306227. ISSN 0028-4793. 
  5. ^ Stefan Mauss et al., ed. (2013). Hepatology 2013 a clinical textbook (PDF) (4th ed. ed.). Düsseldorf: Flying Publisher. ISBN 978-3-924774-90-5. Retrieved 28 April 2014.